Abstract library

40 results for "prophylactic thyroidectomy".
#631 Genotype – Phenotype Correlations and Timing of Prophylactic Thyroidectomy in Patients with Familial Medullary Thyroid Carcinoma
Introduction: Recommendations on the timing of prophylactic thyroidectomy (PTTE) in patients with familial medullary carcinoma (FMTC) are based on classification of RET mutations into four risk levels (ATA 2009).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: prof. MD, PhD Jan Podoba
#2092 Palliative Surgery in Advanced Small Intestinal Neuroendocrine Tumors
Introduction: Small intestinal neuroendocrine tumours (SI-NETs) are known to develop mesenteric metastasis and fibrosis. Since this can induce intestinal obstruction, edema and ischaemia, prophylactic palliative resection of the primary tumour and mesenteric mass is often recommended in case of advanced disease but the evidence is disputable.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Drs. Anela Blazevic
#796 Somatostatin Analogues for Preventing Carcinoid Crisis
Introduction: Carcinoid crisis is a life-threating syndrome of neuroendocrine tumors (NETs) and is characterized by dramatic blood pressure fluctuation, arrhythmias, and bronchospasm. Somatostatin analogues (SSTA) have been recommended for prophylactic administration before provocative procedures.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: LinJie Guo
Authors: Guo L, Tang C, ...
#743 In Vitro Anticancer Effect of Metformin on Neuroendocrine Tumor Cells
Introduction: Patients with multiple endocrine neoplasia (MEN) type 1 develop pancreatic NETs as well as bronchus carcinoids. No prophylactic drug is available yet. Metformin has been reported to act on the AMPK/mTOR signalling pathway and exhibit antitumoral activity in several cancer cell lines.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: George Vlotides
#767 Pancreatic NET Tumors Presenting with Hypercalcitonemia
Introduction: Pancreatic neuroendocrine tumors (pNET) secrete a variety of hormones, but calcitonin secretion rarely occurs.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Biomarkers
Presenting Author: Kalliopi Pazaitou-Panayiotou
#2118 Reassessment of Risk Factors Associated with Locoregional Lymph Nodal Metastases in Well-Differentiated Appendiceal Neuroendocrine Neoplasms
Introduction: To prevent loco-regional recurrence and subsequent development of distant metastases in Appendiceal Neuro-Endocrine Neoplasms (ANEN), the existing Guidelines have identified risk factors which would indicate a prophylactic right hemicolectomy(RHC).
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr. Michail Galanopoulos
#106 Gastroenteropancreatic neuroendocrine tumors: single institution clinicopathological study
Introduction: Neuroendocrine cells are widely distributed throughout the body, and neoplasms from these dispersed cells can arise at many sites. They are distinguished into two broad categories: 1) Tumors identified as small cell lung carcinomas with biology and natural history of a high-grade malignancy and characteristics of small cell undifferentiated or anaplastic appearance by light microscopy. The WHO categorizes these tumors as poorly-differentiated neuroendocrine carcinomas; 2) Well-defined neuroendocrine tumors (NETs) with variable, but most lyindolent biologic behavior and characteristic well-differentiated histologic features. The majority arise in the gastrointestinal tract and collectively they are referred as gastroenteropancreatic neuroendocrine tumors (GEP/NETs). They include carcinoid tumors, pancreatic islet cell tumors (gastrinoma, insulinoma, glucagonoma, VIPoma, somatostatinoma), paragangliomas, pheochromocytomas, and medullary thyroid carcinomas. The WHO classifies the GEP/NETs as well-differentiated NETs (carcinoid tumors) if they are noninvasive and have benign behavior or uncertain malignant potential. In contrast, GEP/NETs with characteristics of low-grade malignancy with invasion of the muscularis propria or beyond, or metastases, are characterized as well-differentiated neuroendocrine carcinomas (malignant carcinoids). Pancreatic islet cell tumors, whether functioning or not, are classified as well-differentiated NETs or well-differentiated neuroendocrine carcinomas, due to the (depending on) histologic characteristics. The WHO classification for gastroenteropancreatic NETs based on stage (ie size and presence of metastases) and grade (mitotic rate, perineural and lymphovascular invasion, Ki-67 proliferative index) categorizes them as well-differentiated NETs, e.g., carcinoid tumors, or as well-differentiated neuroendocrine carcinomas.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Michael M. Vaslamatzis
#299 Clinical and Immunohistochemical Evaluation of Medullary Thyroid Cancer (MTC) and C Cell Hyperplasia (CCH)
Introduction: MTC and CCH has a variable clinical presentation and prognosis and no data are available on the correlation between immunoistochemical (IIC) characterization and clinical behavior.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Prof Laura De Marinis
Authors: Lugli F, Fusco A, Bianchi A, Milardi D, ...
#331 Four-years Follow-up in a Case of Gastric Neuroendocrine Carcinoma
Introduction: Poorly differentiated neuroendocrine carcinoma has a poor prognosis, regardless of the primary site.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Catalina Poiana
#489 Goblet Cell Appendiceal Neuroendocrine Tumors: Diagnosis, Recurrence Rates, Treatment and Survival. A Series of 37 Patients
Introduction: Goblet cell appendiceal neuroendocrine tumors (GCA-NETs) share histologic features of both adenocarcinomas and NETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Christos Toumpanakis